159 related articles for article (PubMed ID: 16854054)
1. Novel sst2-selective somatostatin agonists. Three-dimensional consensus structure by NMR.
Grace CR; Erchegyi J; Koerber SC; Reubi JC; Rivier J; Riek R
J Med Chem; 2006 Jul; 49(15):4487-96. PubMed ID: 16854054
[TBL] [Abstract][Full Text] [Related]
2. Three-dimensional consensus structure of sst2-selective somatostatin (SRIF) antagonists by NMR.
Grace CR; Erchegyi J; Reubi JC; Rivier JE; Riek R
Biopolymers; 2008 Dec; 89(12):1077-87. PubMed ID: 18655144
[TBL] [Abstract][Full Text] [Related]
3. Novel sst(4)-selective somatostatin (SRIF) agonists. 4. Three-dimensional consensus structure by NMR.
Grace CR; Koerber SC; Erchegyi J; Reubi JC; Rivier J; Riek R
J Med Chem; 2003 Dec; 46(26):5606-18. PubMed ID: 14667215
[TBL] [Abstract][Full Text] [Related]
4. Somatostatin receptor 1 selective analogues: 4. Three-dimensional consensus structure by NMR.
Grace CR; Durrer L; Koerber SC; Erchegyi J; Reubi JC; Rivier JE; Riek R
J Med Chem; 2005 Jan; 48(2):523-33. PubMed ID: 15658866
[TBL] [Abstract][Full Text] [Related]
5. Novel sst(4)-selective somatostatin (SRIF) agonists. 1. Lead identification using a betide scan.
Rivier J; Erchegyi J; Hoeger C; Miller C; Low W; Wenger S; Waser B; Schaer JC; Reubi JC
J Med Chem; 2003 Dec; 46(26):5579-86. PubMed ID: 14667212
[TBL] [Abstract][Full Text] [Related]
6. Novel sst(4)-selective somatostatin (SRIF) agonists. 2. Analogues with beta-methyl-3-(2-naphthyl)alanine substitutions at position 8.
Erchegyi J; Penke B; Simon L; Michaelson S; Wenger S; Waser B; Cescato R; Schaer JC; Reubi JC; Rivier J
J Med Chem; 2003 Dec; 46(26):5587-96. PubMed ID: 14667213
[TBL] [Abstract][Full Text] [Related]
7. Novel sst(4)-selective somatostatin (SRIF) agonists. 3. Analogues amenable to radiolabeling.
Erchegyi J; Waser B; Schaer JC; Cescato R; Brazeau JF; Rivier J; Reubi JC
J Med Chem; 2003 Dec; 46(26):5597-605. PubMed ID: 14667214
[TBL] [Abstract][Full Text] [Related]
8. A light-activated beta-turn scaffold within a somatostatin analog: NMR structure and biological activity.
Ulysse LG; Chmielewski J
Chem Biol Drug Des; 2006 Feb; 67(2):127-36. PubMed ID: 16492160
[TBL] [Abstract][Full Text] [Related]
9. Novel sst5-selective somatostatin dicarba-analogues: synthesis and conformation-affinity relationships.
D'Addona D; Carotenuto A; Novellino E; Piccand V; Reubi JC; Di Cianni A; Gori F; Papini AM; Ginanneschi M
J Med Chem; 2008 Feb; 51(3):512-20. PubMed ID: 18210999
[TBL] [Abstract][Full Text] [Related]
10. Drug design at peptide receptors: somatostatin receptor ligands.
Hannon JP; Nunn C; Stolz B; Bruns C; Weckbecker G; Lewis I; Troxler T; Hurth K; Hoyer D
J Mol Neurosci; 2002; 18(1-2):15-27. PubMed ID: 11931345
[TBL] [Abstract][Full Text] [Related]
11. N-Methyl scan of somatostatin octapeptide agonists produces interesting effects on receptor subtype specificity.
Rajeswaran WG; Hocart SJ; Murphy WA; Taylor JE; Coy DH
J Med Chem; 2001 Apr; 44(9):1416-21. PubMed ID: 11311064
[TBL] [Abstract][Full Text] [Related]
12. 2-pyridylthioureas: novel nonpeptide somatostatin agonists with SST4 selectivity.
Liu S; Crider AM; Tang C; Ho B; Ankersen M; Stidsen CE
Curr Pharm Des; 1999 Apr; 5(4):255-63. PubMed ID: 10101224
[TBL] [Abstract][Full Text] [Related]
13. Novel, potent, and radio-iodinatable somatostatin receptor 1 (sst1) selective analogues.
Erchegyi J; Cescato R; Grace CR; Waser B; Piccand V; Hoyer D; Riek R; Rivier JE; Reubi JC
J Med Chem; 2009 May; 52(9):2733-46. PubMed ID: 19351180
[TBL] [Abstract][Full Text] [Related]
14. Intracerebroventricular injection of somatostatin sst5 receptor agonist inhibits gastric acid secretion in rats.
Martínez V; Coy DH; Lloyd KC; Taché Y
Eur J Pharmacol; 1996 Jan; 296(2):153-60. PubMed ID: 8838451
[TBL] [Abstract][Full Text] [Related]
15. Conformational analysis of a potent SSTR3-selective somatostatin analogue by NMR in water solution.
Gairí M; Saiz P; Madurga S; Roig X; Erchegyi J; Koerber SC; Reubi JC; Rivier JE; Giralt E
J Pept Sci; 2006 Feb; 12(2):82-91. PubMed ID: 16365912
[TBL] [Abstract][Full Text] [Related]
16. Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists.
Cescato R; Schulz S; Waser B; Eltschinger V; Rivier JE; Wester HJ; Culler M; Ginj M; Liu Q; Schonbrunn A; Reubi JC
J Nucl Med; 2006 Mar; 47(3):502-11. PubMed ID: 16513620
[TBL] [Abstract][Full Text] [Related]
17. Native somatostatin sst2 and sst5 receptors functionally coupled to Gi/o-protein, but not to the serum response element in AtT-20 mouse tumour corticotrophs.
Cervia D; Fehlmann D; Hoyer D
Naunyn Schmiedebergs Arch Pharmacol; 2003 Jun; 367(6):578-87. PubMed ID: 12750875
[TBL] [Abstract][Full Text] [Related]
18. Functional characterisation of the putative somatostatin sst2 receptor antagonist CYN 154806.
Nunn C; Schoeffter P; Langenegger D; Hoyer D
Naunyn Schmiedebergs Arch Pharmacol; 2003 Jan; 367(1):1-9. PubMed ID: 12616335
[TBL] [Abstract][Full Text] [Related]
19. Porcine somatostatin receptor 2 displays typical pharmacological sst2 features but unique dynamics of homodimerization and internalization.
Durán-Prado M; Bucharles C; Gonzalez BJ; Vázquez-Martínez R; Martínez-Fuentes AJ; García-Navarro S; Rhodes SJ; Vaudry H; Malagón MM; Castaño JP
Endocrinology; 2007 Jan; 148(1):411-21. PubMed ID: 17053026
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study.
Bertherat J; Tenenbaum F; Perlemoine K; Videau C; Alberini JL; Richard B; Dousset B; Bertagna X; Epelbaum J
J Clin Endocrinol Metab; 2003 Nov; 88(11):5353-60. PubMed ID: 14602773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
